The trial, backed by the National Institutes of Health (NIH), is designed to determine if the vaccine, mRNA-1273, can prevent coronavirus infection, limit virus in the nose, and reduce transmission from vaccinated individuals to their close contacts.
The Prevent COVID U study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), will monitor about 12,000 young adults across 20 universities over a five-month period.